DRP Journal

Discover Research Profit

Finance 

H-CYTE Inc (OTCMKTS:HCYT) Stock To Watch: Company Completes Acquisition of SkinDisc™ Regenerative Tissue Kit

Ash K , , , ,

The completion of an acquisition is almost always seen one way or another by investors and the price action in the stock provides a clue as to what they think.

Trading Data

On Thursday, HCYT stock decreased 0.38% to $2.6300 with more than 168 shares, compared to its average volume of 22 shares. The stock moved within a range of $2.6300 – 2.6300 after opening trade at $2.6300.

H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC

One of the companies that could come on to the radars of investors this morning is the medical biosciences firm H-CYTE Inc (OTCMKTS:HCYT), which announced on Thursday that it had completed the acquisition SkinDisc. In this situation, it could be a good idea for investors to perhaps take a closer look at how the acquisition may have an impact on the company’s business. One of the things that needs to be pointed out is that the acquisition is going to help the company in further diversifying its portfolio of assets.

On the other hand, the application development by SkinDisc also displayed statistically significant results when compared to current treatments related to limb salvaging and wound healing. At this point in time, SkinDisc is in contact with the United States Food and Drugs Administration with regards to its application.

In addition to that, the company has already established contact with a manufacturer. Up until now, in excess of 500 patients have been treated with the application and hence, it is an acquisition that could prove to be a major long term boost for H-CYTE Inc.

Key Quote

“The completed acquisition of SkinDisc™ marks a pivotal moment for the Company, representing our second closing of a potentially life-saving technology asset under development in the past four months,” said Michael Yurkowsky, H-CYTE’s Chief Executive Officer. “Acquiring a proprietary technology like SkinDisc™ highlights our ability to add attractive assets to our product portfolio as we evolve into a leading hybrid biopharmaceutical company. The H-CYTE team is excited to enter the wound healing and limb salvage space, which has a $2 billion total addressable market opportunity. SkinDisc™ will position the Company to combat the rising prevalence of acute, chronic, and surgical wounds with an effective and affordable treatment. We expect to submit a De Novo 510(k) pathway request for SkinDisc™ in the first half of 2023.”